Abstracts tagged "Early Rheumatoid Arthritis"

Abstract Number: 1515 • 2016 ACR/ARHP Annual Meeting
Could Increase Levels of Dickkopf-1 Protein be Considered As a Potential Biomarker for Bone Resorption in Joint and Periodontal Disease in Patients with Early Rheumatoid Arthritis?
ANA MARIA HEREDIA PALAU¹, SEBASTIAN GIRALDO QUINTERO^2,3, JULIETTE DE AVILA¹, LORENA CHILA MORENO⁴, GLORIA LAFAURIE⁵, CONSTANZA RODRIGUEZ⁴, WILSON BAUTISTA-MOLANO^5,6, PHILLIPE CHALEM CHOUEKA⁷, JUAN MANUEL BELLO GUALTEROS^3,8, RAFAEL VALLE-OÑATE^3,8 and CONSUELO ROMERO-SÁNCHEZ^4,9,10, ¹Unit of Oral Basic Investigation-UIBO, School of Dentistry, Universidad El Bosque, Bogota, Colombia, ²Rheumatology and Immunology Department,Hospital Militar Central, Bogota, Colombia, ³School of Medicine, Universidad Militar Nueva Granada, Bogota, Colombia, ⁴Unit of Oral Basic Investigation-UIBO, School of Dentistry, Universidad El Bosque, BOGOTA, Colombia, ⁵Unit of Oral Basic Investigation-UIBO, School of Dentistry, Universidad El Bosque, Bogotá, Colombia, ⁶School of Medicine, Universidad Militar Nueva Granada, Bogotá, Colombia, ⁷Fundación Instituto de Reumatología Fernando Chalem, Bogotá, Colombia, ⁸Rheumatology and Immunology, Hospital Militar Central, Bogota, Colombia, ⁹Rheumatology and Immunology Department,Hospital Militar Central, BOGOTA, Colombia, ¹⁰School of Medicine, Universidad Militar Nueva Granada, BOGOTA, Colombia
Background/Purpose: Periodontitis and rheumatoid arthritis (RA) are chronic destructive inflammatory diseases with significant worldwide prevalence. They are characterized by inflammatory lesions adjacent to bone destruction…
Abstract Number: 3217 • 2016 ACR/ARHP Annual Meeting
Broad-Based Interrogation of the Serum Proteome Suggests That RA Onset Is Associated with Activation of the Intrinsic Coagulation Cascade
Liam O'Neil¹, Xiaobo Meng², Irene Smolik³, Carol Hitchon² and Hani El-Gabalawy⁴, ¹Rheumatology, University of Manitoba, Winnipeg, MB, Canada, ²University of Manitoba, Winnipeg, MB, Canada, ³Arthritis Center, University of Manitoba, Winnipeg, MB, Canada, ⁴University of Manitoba Arthritis Center, Winnipeg, MB, Canada
Background/Purpose: The establishment of longitudinal pre-clinical RA cohorts is beginning to provide important insights into the mechanisms that precede the onset of clinically detectable disease.…
Abstract Number: 567 • 2016 ACR/ARHP Annual Meeting
Understanding Contextual Factors That Influence Decisions Related to Health and Work Among People with Recently Diagnosed Rheumatoid Arthritis
Graham Macdonald¹, Catherine Backman², Anne F. Townsend³ and Linda Li⁴, ¹Occupational Science and Occupational Therapy, University of British Columbia, Vancouver, BC, Canada, ²Occup Science & OccupTherapy, University of British Columbia, Vancouver, BC, Canada, ³Qualitative Research, Arthritis Research Centre of Canada, Richmond, BC, Canada, ⁴Department of Physical Therapy, The University of British Columbia, Vancouver, BC, Canada
Background/Purpose: In rheumatoid arthritis (RA), early diagnosis and treatment are essential to better outcomes. Many people defer seeking help or treatment for reasons that are…
Abstract Number: 1649 • 2016 ACR/ARHP Annual Meeting
Influence of Modifiable Risk Factors on the Response to MTX Alone in Early RA Patients
Eugenio Chamizo Carmona¹, Carmen Carrasco-Cubero², Juan Jose Aznar Sánchez³, Raul Veroz Gonzalez³, Tamara Libertad Rodriguez Araya¹, Piter José Cossio Jimenez³ and Lara Chaves Chaparro¹, ¹Rheumatology, Hospital de Mérida, Mérida, Spain, ²Rheumatology, Complejo Universitario de Badajoz, Badajoz, Spain, ³Hospital de Mérida, Mérida, Spain
Background/Purpose: The aim of early RA treatment is remission. Intensive treatment with MTX and treat-to-target approach achieve remission in 30-50% patients. Modifiable risk factors, as…
Abstract Number: 3226 • 2016 ACR/ARHP Annual Meeting
Maintenance of Clinical Remission and Radiographic Non-Progression with MTX after Completion of 1 Year Initial Treatment with Certolizumab Pegol in Japanese Patients with Early Rheumatoid Arthritis
Yoshiya Tanaka¹, Tatsuya Atsumi², Kazuhiko Yamamoto³, Tsutomu Takeuchi⁴, Hisashi Yamanaka⁵, Naoki Ishiguro⁶, Katsumi Eguchi⁷, Akira Watanabe⁸, Hideki Origasa⁹, Toshiharu Shoji¹⁰, Pauline Ralston¹¹, Désirée van der Heijde¹², Nobuyuki Miyasaka^13,14 and Takao Koike¹⁵, ¹University of Occupational and Environmental Health, Kitakyushu, Japan, ²Division of Rheumatology, Endocrinology and Nephrology, Hokkaido University Graduate School of Medicine, Sapporo, Japan, ³The University of Tokyo, Tokyo, Japan, ⁴Division of Rheumatology, Keio University School of Medicine, Tokyo, Japan, ⁵Tokyo Women's Medical University, Tokyo, Japan, ⁶Nagoya University, Nagoya, Japan, ⁷Department of Rheumatology, Sasebo Chuo Hospital, Sasebo, Japan, ⁸Tohoku University, Sendai, Japan, ⁹Division of Biostatistics and Clinical Epidemiology, University of Toyama School of Medicine, Toyama, Japan, ¹⁰UCB Pharma, Tokyo, Japan, ¹¹Hays Pharma, London, United Kingdom, ¹²Leiden University Medical Center, Leiden, Netherlands, ¹³Department of Medicine and Rheumatology, Tokyo Medical and Dental University, Tokyo, Japan, ¹⁴Tokyo Medical and Dental University, Tokyo, Japan, ¹⁵Sapporo Medical Center NTT EC, Sapporo, Japan
Background/Purpose: The efficacy and safety of certolizumab pegol (CZP) treatment in combination with dose-optimized MTX in Japanese MTX-naïve early RA patients (pts) with poor prognostic…
Abstract Number: 593 • 2016 ACR/ARHP Annual Meeting
Adalimumab (HUMIRA) Halts Radiographic Progression and Reduces Disease Activity in Patients with a Poor Initial Response to Methotrexate
Josef S. Smolen¹, Ronald F. van Vollenhoven², Benjamin A. Wolfe³, Su Chen³, Jessica L. Suboticki³ and Arthur Kavanaugh⁴, ¹Division of Rheumatology, Department of Medicine, Medical University of Vienna, and Hietzing Hospital, Vienna, Austria, ²Amsterdam Rheumatology and Immunology Center (ARC), Amsterdam, Netherlands, ³AbbVie Inc., North Chicago, IL, ⁴Division of Rheumatology, Allergy, and Immunology, University of California – San Diego, La Jolla, CA
Background/Purpose: In patients (pts) with early rheumatoid arthritis (RA), conventional synthetic DMARDs (csDMARDs), preferably methotrexate (MTX), are recommended as first line therapy.1,2 For pts who…
Abstract Number: 2246 • 2016 ACR/ARHP Annual Meeting
Glucocorticoids in Early Rheumatoid Arthritis Management, Friend or Foe?
Diederik Decock¹, Rene Westhovens^1,2, Veerle Stouten¹, Kristien Van der Elst^2,3, Johan Joly², Patrick Verschueren^1,2 and CareRA Study Group, ¹KU Leuven Department of Development and Regeneration, Skeletal Biology and Engineering Research Center, Leuven, Belgium, ²Rheumatology, University Hospitals Leuven, Leuven, Belgium, ³KU Leuven, Department of Public Health and Primary Care, Skeletal Biology and Engineering Research Center, Leuven, Belgium
Background/Purpose: ≥≥140/90 mmHg The only difference between treatments arms in either risk groups was a BMI decrease in Avant-Garde compared to Classic and Slim between baseline…
Abstract Number: 594 • 2016 ACR/ARHP Annual Meeting
Maintenance of Improvements in Patients’ Physical Function, Workplace and Household Productivity, and Reduction in Caregiver Burden with 2 Years of Certolizumab Pegol Treatment in DMARD-Naive, Early RA Patients with Severe Progressive Disease
Clifton Bingham III¹, Paul Emery², Michael Weinblatt³, Gerd-Rüdiger Burmester⁴, Daniel E. Furst⁵, Xavier Mariette⁶, Ronald van Vollenhoven⁷, Brenda VanLunen⁸, Oana Purcaru⁹ and Vivian P. Bykerk¹⁰, ¹Johns Hopkins University, Baltimore, MD, ²University of Leeds, Leeds, United Kingdom, ³Brigham and Women’s Hospital, Boston, MA, ⁴Charité – University Medicine Berlin, Berlin, Germany, ⁵David Geffen School of Medicine at UCLA, Los Angeles, CA, ⁶Université Paris-Sud, Paris, France, ⁷Amsterdam Rheumatology and Immunology Center (ARC), Amsterdam, Netherlands, ⁸UCB Pharma, Raleigh, NC, ⁹UCB Pharma, Slough, United Kingdom, ¹⁰Divison of Rheumatology, Hospital for Special Surgery, New York, NY
Background/Purpose: Rheumatoid arthritis (RA) is associated with loss of physical function, work disability, and decreased quality of life. Early treatment with certolizumab pegol (CZP) in…
Abstract Number: 2262 • 2016 ACR/ARHP Annual Meeting
CR6086 a New Potent EP4 Receptor Antagonist with Immunomodulatory Activities
Tiziana Piepoli¹, Daniele Maggioni², Silvia Zerbi¹, Anna Stucchi¹, Laura Mennuni¹, Marco Lanza¹, Gianfranco Caselli¹ and Lucio Claudio Rovati¹, ¹Rottapharm Biotech, Monza, Italy, ²School of Medicine and Surgery, University of Milano-Bicocca, Monza, Italy
Background/Purpose: In the early phase of rheumatoid arthritis (RA), PGE2 recruits different immune cells from the blood stream into target tissues. Via the EP4 receptor,…
Abstract Number: 595 • 2016 ACR/ARHP Annual Meeting
Cinical Responses and Improvements in Patient-Reported Outcomes Are Associated with Increased Productivity in the Workplace and at Home in Rheumatoid Arthritis Patients Treated with Certolizumab Pegol
Vivian P. Bykerk¹, Paul Emery², Michael Weinblatt³, Gerd-Rüdiger Burmester⁴, Daniel E. Furst⁵, Xavier Mariette⁶, Ronald van Vollenhoven⁷, Oana Purcaru⁸, Pauline Ralston⁹ and Clifton Bingham III¹⁰, ¹Divison of Rheumatology, Hospital for Special Surgery, New York, NY, ²University of Leeds, Midlothian, United Kingdom, ³Brigham and Women’s Hospital, Boston, MA, ⁴Charité – University Medicine Berlin, Berlin, Germany, ⁵David Geffen School of Medicine at UCLA, Los Angeles, CA, ⁶Université Paris-Sud, Paris, France, ⁷Amsterdam Rheumatology and Immunology Center (ARC), Amsterdam, Netherlands, ⁸UCB Pharma, Slough, United Kingdom, ⁹Hays Pharma, London, United Kingdom, ¹⁰Johns Hopkins University, Baltimore, MD
Background/Purpose: Rheumatoid arthritis (RA) is associated with work disability, loss of productivity and reduced quality of life. In established and early RA, compared with MTX…
Abstract Number: 2480 • 2016 ACR/ARHP Annual Meeting
Dose-Related Short Term Clinical Response to Initial Treatment with Methotrexate in Mono- and Combination Therapy in Early Rheumatoid Arthritis Patients – a Meta-Regression Analysis
SA Bergstra¹, CF Allaart¹, T Stijnen² and RBM Landewé^3,4, ¹Department of Rheumatology, LUMC, Leiden, Netherlands, Leiden, Netherlands, ²Department of Medical Statistics, LUMC, Leiden, Netherlands, Leiden, Netherlands, ³Zuyderland Medical Center, Heerlen, Netherlands, Heerlen, Netherlands, ⁴Amsterdam Rheumatology & Immunology Center, Netherlands, Amsterdam, Netherlands
Background/Purpose: Recently, there has been a trend to start methotrexate (MTX) in higher doses, either as monotherapy or in combination with other drugs in rheumatoid…
Abstract Number: 608 • 2016 ACR/ARHP Annual Meeting
Initial Intensive Therapy of Adalimumab and Methotrexate Is Associated with Long-Term Structural Remission and Low Disease Activity after Adalimumab Discontinuation Is Maintained up to 3 Years in Japanese Patients: Hopeful-3 Study
Yoshiya Tanaka¹, Hisashi Yamanaka², Naoki Ishiguro³, Nobuyuki Miyasaka⁴, Katsuyoshi Kawana⁵, Naoki Agata⁵ and Tsutomu Takeuchi⁶, ¹University of Occupational and Environmental Health, Kitakyushu, Japan, ²Tokyo Women's Medical University, Tokyo, Japan, ³Department of Orthopedic Surgery, Nagoya University, Graduate School & Faculty of Medicine, Nagoya, Japan, ⁴Tokyo Medical and Dental University, Tokyo, Japan, ⁵Abbvie GK, Tokyo, Japan, ⁶Division of Rheumatology, Keio University School of Medicine, Tokyo, Japan
Background/Purpose: Methods: Of 172 patients enrolled, 135 (ADA continuation, n=61; ADA discontinuation, n=74) with DAS28–CRP at both week 52 (start of HOPEFUL-2) and week 208…
Abstract Number: 2498 • 2016 ACR/ARHP Annual Meeting
Tender Joints Is a Consistent Negative Predictor of Sustained Remission in Aggressively Treated Patients with Early Rheumatoid Arthritis
Nina P. Sundlisater¹, Siri Lillegraven¹, Inge C Olsen¹, Anna-Birgitte Aga¹, Hilde B. Hammer², Till Uhlig¹, Desiree van der Heijde^1,3, Tore K Kvien¹ and Espen A. Haavardsholm¹, ¹Dept. of Rheumatology, Diakonhjemmet Hospital, Oslo, Norway, ²Dept. of Rheumtology, Diakonhjemmet Hospital, Oslo, Norway, ³Dept of Rheumatology, Leiden University Medical Ctr, Leiden, Netherlands
Background/Purpose: Rheumatoid arthritis (RA) care has moved towards early diagnosis and treatment to improve long-term patient outcomes. Our objective was to assess prognostic factors for…
Abstract Number: 952 • 2016 ACR/ARHP Annual Meeting
A Randomized, Double-Blind, Placebo-Controlled Phase 3 Study Evaluating Treatment Strategies (Continuation Versus Withdrawal) for Maintaining Low Disease Activity after 1 Year of Certolizumab Pegol in DMARD-Naive Patients with Early and Progressive, Active RA
Michael Weinblatt¹, Clifton Bingham III², Gerd-Rüdiger Burmester³, Vivian P. Bykerk⁴, Daniel E. Furst⁵, Xavier Mariette⁶, Désirée van der Heijde⁷, Ronald van Vollenhoven⁸, Brenda VanLunen⁹, Cécile Ecoffet¹⁰, Christopher Cioffi⁹ and Paul Emery¹¹, ¹Brigham and Women's Hospital, Boston, MA, ²Johns Hopkins University, Baltimore, MD, ³Charité – University Medicine Berlin, Berlin, Germany, ⁴Divison of Rheumatology, Hospital for Special Surgery, New York, NY, ⁵David Geffen School of Medicine at UCLA, Los Angeles, CA, ⁶Université Paris-Sud, Paris, France, ⁷Leiden University Medical Center, Leiden, Netherlands, ⁸Amsterdam Rheumatology and Immunology Center (ARC), Amsterdam, Netherlands, ⁹UCB Pharma, Raleigh, NC, ¹⁰UCB Pharma, Brussels, Belgium, ¹¹University of Leeds, Leeds, United Kingdom
Background/Purpose: There is interest in tapering or stopping biologic DMARD therapy in RA patients (pts) who have achieved sustained disease control.1 We report the results…
Abstract Number: 2525 • 2016 ACR/ARHP Annual Meeting
Patient Characteristics Predicting Remission Using Intensive Treatment Strategies in Early Rheumatoid Arthritis
Diederik Decock¹, Rene Westhovens^1,2, Veerle Stouten¹, Kristien Van der Elst^2,3, Johan Joly², Patrick Verschueren^1,2 and CareRA study group, ¹KU Leuven Department of Development and Regeneration, Skeletal Biology and Engineering Research Center, Leuven, Belgium, ²Rheumatology, University Hospitals Leuven, Leuven, Belgium, ³KU Leuven, Department of Public Health and Primary Care, Skeletal Biology and Engineering Research Center, Leuven, Belgium
Background/Purpose: Guidelines recommend to treat newly diagnosed Early Rheumatoid Arthritis (ERA) with intensive treatment strategies using Methotrexate (MTX) or a combination of csDMARDs and a…

« Previous Page
1
…
7
8
9
10
11
…
18
Next Page »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

ACR Abstract Embargo Policy

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. Academic institutions, private organizations and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part a scientific presentation or presentation of additional new information that will be available at the time of the meeting) is under embargo until Saturday, November 11, 2023.

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying financial and other sponsors about this policy. If you have questions about the abstract embargo policy, please contact the public relations department at [email protected].

Copyright Policy

View ACR Policies.